carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multipelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
tecvayli
janssen-cilag international n.v. - teclistamab - multipelt myelom - antineoplastiske midler - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
talvey
janssen-cilag international n.v. - talquetamab - multipelt myelom - antineoplastiske midler - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
arava
sanofi-aventis deutschland gmbh - leflunomid - arthritis, rheumatoid; arthritis, psoriatic - immunosuppressiva - leflunomid er indiceret til behandling af voksne patienter med aktiv leddegigt, som en 'sygdomsmodificerende antireumatiske stof" (dmard);aktiv psoriasis artrit. senere eller samtidig behandling med hepatotoksiske eller haematotoxic dmard (e. methotrexat) kan resultere i en øget risiko for alvorlige bivirkninger; derfor skal indledningen af leflunomidbehandling nøje overvejes med hensyn til disse fordele / risikofaktorer. desuden skifter fra leflunomid til en anden dmard uden at følge udvaskningen procedure kan også øge risikoen for alvorlige bivirkninger selv i lang tid efter skifte.
sileo
orion corporation - dexmedetomidine hydrochloride - nervesystemet, andre sovemidler og beroligende midler - hunde - lindring af akut angst og frygt, der er forbundet med støj hos hunde.
praxbind
boehringer ingelheim international gmbh - idarucizumab - blødning - alle andre terapeutiske produkter - praxbind er en bestemt vending agent for dabigatran og er indiceret hos voksne patienter, som behandles med pradaxa (dabigatran etexilate), når hurtig vending af dets antikoagulerende virkning er nødvendig:for akut kirurgi/akutte procedurer ved livstruende eller ukontrolleret blødning.
fenemal "sad" 100 mg/ml injektionsvæske, opløsning
amgros i/s - phenobarbital - injektionsvæske, opløsning - 100 mg/ml
fenemal "sad" 10 mg/ml injektionsvæske, opløsning
amgros i/s - phenobarbital - injektionsvæske, opløsning - 10 mg/ml
flumazenil "hameln" 0,1 mg/ml injektions-/infusionsvæske, opløsning
hameln pharma gmbh - flumazenil - injektions-/infusionsvæske, opløsning - 0,1 mg/ml